Treatment of @entity2010 complicated by XXXX with @entity16860 and @entity12880 .

@entity1 @entity12880 @entity6 @entity5463 @entity1421 @entity17258 @entity16860 @entity2010
A @entity1 with severe @entity2010 , complicated by @entity6 , was first treated with a combination o @entity12880 and @entity16860 . Urine volume dropped from 18 litres/day ( @entity17258 = 10.5 ml/min) to 3.1-5.1 litres/day ( @entity17258 = -0.1 -+1.1 ml/min) under treatment. Ten months after the beginning of therapy treatment was maintained with @entity16860 alone; no significant rise in urine volume was observed. After 18 months when therapy was stopped for 5 days urine volume rose to 11.7 litres/day maximum ( @entity17258 = 6.6 ml/min). No obvious side effects occurred under treatment during a follow up for over 18 months. Serum levels for @entity5463 before and under treatment were below 1.0 pg/ml. Determination of free water clearance ( @entity17258 ) proved to be a highly sensitive and simple method for follow up controls. It is discussed whether the coincidental manifestation of @entity2010 and @entity6 may be caused by a single molecular lesion. This hypothesis is supported by data which imply that in both disease @entity16860 acts via a common molecular mechanism, the blocking of endogenous @entity1421 biosynthesis. Finally a treatment with oral "non-hormonal" drugs like @entity12880 and @entity16860 should be taken into consideration in some cases of @entity2010 as is demonstrated by this case report.
